Forty-two patients (91.3%) experienced treatment-related AEs (TRAEs), the most common being anemia (32.6%), elevated α-hydroxybutyrate dehydrogenase (28.3%) and elevated alanine aminotransferase (26.1%). Here, GPT is linked to anemia (phenotype).